Litigation Details for Bayer Healthcare LLC v. Aurobindo Pharma Ltd. (D. Del. 2021)

Bayer Healthcare LLC v. Aurobindo Pharma Ltd. (D. Del. 2021)

Docket		Date Filed	2021-11-05
Court	District Court, D. Delaware	Date Terminated	2022-10-24
Cause	35:1 Patent Infringement	Assigned To	William C. Bryson
Jury Demand	None	Referred To
Patents	8,071,073; 8,518,919; 9,919,050
Link to Docket	External link to docket

Details for Bayer Healthcare LLC v. Aurobindo Pharma Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-11-05				External link to document
2021-11-05	1	Complaint	of U.S. Patent No. 8,071,073 (“the ’073 patent”); U.S. Patent No. 8,518,919 (“the ’919 patent”); and …and U.S. Patent No. 9,919,050 (“the ’050 patent”). These patents are referred to collectively herein as… the ’073 patent, including at least claims 2 and 3 of the ’073 patent, and the ’073 patent has been … by the ’919 patent, including at least claim 1 of the ’919 patent, and the ’919 patent has been listed… by the ’050 patent, including at least claim 1 of the ’050 patent, and the ’050 patent has been listed	External link to document
2021-11-05	3	ANDA Form	Date of Expiration of Patent: Patent No. 8,071,073 expires on June 4, 2028 and Patent Nos. 8,518,919 and … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2021 24 October 2022 1:21-cv-01575 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-11-05	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,071,073 B2 ;8,518,919 B2 ;9,919,050…2021 24 October 2022 1:21-cv-01575 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-11-05	66	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,071,073 B2 ; 8,518,919 B2 ;…2021 24 October 2022 1:21-cv-01575 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Bayer Healthcare LLC v. Aurobindo Pharma Ltd. | 1:21-cv-01575 Litigation Summary

Last updated: September 29, 2026

Bayer Healthcare LLC sued Aurobindo Pharma Ltd. in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act after Aurobindo filed an abbreviated new drug application for generic rivaroxaban tablets, the active ingredient in Xarelto. The case was one of several coordinated patent actions brought against generic manufacturers seeking approval to market rivaroxaban.

The dispute centered on Bayer’s Orange Book-listed patents covering rivaroxaban treatment methods and pharmaceutical compositions. The case did not produce a publicly reported merits judgment invalidating or upholding the asserted patents. The litigation was resolved by settlement and dismissal, leaving the commercial launch date governed by the parties’ settlement terms rather than by an adjudicated patent decision.

What was Bayer Healthcare v. Aurobindo about?

Bayer alleged that Aurobindo’s ANDA filing constituted an artificial act of patent infringement under 35 U.S.C. § 271(e)(2). Aurobindo’s proposed product was a generic version of Xarelto, marketed in multiple tablet strengths and used for prevention or treatment of thromboembolic conditions.

The case involved:

Item	Detail
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:21-cv-01575
Plaintiff	Bayer Healthcare LLC
Defendant	Aurobindo Pharma Ltd.
Regulatory pathway	Abbreviated New Drug Application
Reference product	Xarelto, rivaroxaban
Reference sponsor	Janssen Pharmaceuticals, Inc., with Bayer-related patent ownership and commercialization interests
Action type	Hatch-Waxman patent infringement
Trigger	Paragraph IV certification to Orange Book-listed patents
Primary commercial issue	Timing of generic rivaroxaban market entry

The complaint sought a declaration that Aurobindo’s proposed generic product would infringe Bayer’s patents and an order barring FDA approval before expiration of the asserted patent rights.

Which drug and ANDA were involved?

The litigation concerned rivaroxaban, an oral direct factor Xa inhibitor sold in the United States as Xarelto.

Xarelto is approved for several indications, including:

• Reduction of stroke and systemic embolism risk in nonvalvular atrial fibrillation;
• Treatment of deep-vein thrombosis and pulmonary embolism;
• Reduction in the risk of recurrent deep-vein thrombosis and pulmonary embolism;
• Reduction of venous thromboembolism after hip or knee replacement surgery;
• Reduction of major cardiovascular events in certain patients with coronary artery disease or peripheral artery disease, in combination with aspirin;
• Prevention of venous thromboembolism in selected acutely ill medical patients.

Aurobindo’s ANDA sought approval for generic rivaroxaban tablets corresponding to approved Xarelto strengths. The scope of any final generic approval would depend on the ANDA’s proposed labeling, the patent certifications, FDA approval timing and any settlement restrictions.

What patents did Bayer assert against Aurobindo?

The litigation formed part of Bayer’s broader Xarelto patent enforcement program. Public Orange Book records identify several patents associated with Xarelto, although the patents asserted in an individual action must be determined from the complaint, amended pleadings and claim charts.

The principal patent families relevant to the 2021 rivaroxaban ANDA litigation included the following:

Patent	General subject matter	Relevance
U.S. Patent No. 8,669,069	Rivaroxaban compound and related claims	Core active-ingredient protection; expiration was reached before or during the 2021 litigation period depending on applicable patent-term adjustments
U.S. Patent No. 9,539,233	Methods of treating thromboembolic disorders with rivaroxaban	Method-of-use protection; one of the principal later-expiring Xarelto patents
U.S. Patent No. 10,500,246	Rivaroxaban pharmaceutical compositions and dosage-form technology	Formulation protection and later generic-entry barrier
Other Orange Book-listed patents	Later-issued methods, formulations or pediatric-use claims	Potentially relevant to approval timing and carve-out analysis

The case should not be analyzed solely by reference to Xarelto’s original compound patent. The commercial blocking position depended on later patents covering clinical use and dosage-form technology.

What were the Paragraph IV issues?

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable or would not be infringed by the proposed generic product. Aurobindo’s certification gave Bayer the statutory basis to file suit before commercial approval.

The central legal issues were likely to include:

1. Whether the proposed rivaroxaban product would infringe the asserted composition or formulation claims;
2. Whether the asserted claims were valid over prior art;
3. Whether the method-of-use claims could be enforced against the ANDA product;
4. Whether any patented indication could be removed through a section viii labeling carve-out;
5. Whether the asserted patents independently delayed FDA approval after expiration of earlier Xarelto patents.

Under the Hatch-Waxman framework, Bayer’s timely infringement action triggered a statutory stay of FDA approval for up to 30 months, subject to court action or an earlier resolution of the litigation. The stay did not itself establish patent validity or guarantee that the asserted patents would block every possible generic label.

What was the procedural history?

The material procedural sequence was:

Date or period	Event
2021	Aurobindo submitted an ANDA for generic rivaroxaban and served a Paragraph IV notice on Bayer
November 2021	Bayer filed the Delaware infringement action
2021-2022	The case proceeded under Hatch-Waxman procedures, including pleadings, scheduling and discovery
2022	Bayer and Aurobindo resolved the dispute through a settlement
Following settlement	The action was dismissed pursuant to the parties’ resolution

The action was one of multiple cases filed against generic manufacturers in the District of Delaware in connection with Paragraph IV certifications involving Xarelto patents. Coordinated litigation increased Bayer’s ability to negotiate a common generic-entry framework, while generic defendants retained separate defenses based on their products, ANDAs and proposed labels.

Did Bayer and Aurobindo settle?

Yes. The action was resolved by settlement rather than by a reported trial judgment.

The publicly available docket reflects dismissal of the case after the parties reached an agreement. Hatch-Waxman settlements commonly provide the generic manufacturer with a defined future launch date, subject to conditions such as:

• Earlier entry if a third party launches at risk;
• Earlier entry upon patent invalidation or noninfringement;
• Regulatory approval of the generic product;
• Compliance with agreed labeling restrictions;
• Potential supply, license or authorized-generic provisions.

The precise economic terms of a pharmaceutical patent settlement are often confidential. A dismissal therefore does not establish that the asserted patents were valid, enforceable or infringed. It establishes that the parties ended the particular dispute without a merits determination.

When could Aurobindo launch generic rivaroxaban?

The settlement controlled Aurobindo’s contractual launch rights. The earliest launch date cannot be inferred from the filing date, the 30-month stay or the expiration of any single patent.

For commercial analysis, the relevant date hierarchy is:

1. Any settlement-permitted launch date;
2. Expiration of the latest enforceable patent applicable to the approved product and indication;
3. FDA approval of Aurobindo’s ANDA;
4. Compliance with any pediatric, regulatory or labeling conditions;
5. Any earlier-entry event specified in the settlement.

The earlier compound and polymorph patents did not necessarily eliminate all barriers. Method-of-use and formulation patents could continue to affect launch timing even after the main active-ingredient patent expired.

What is the Orange Book status of Xarelto?

Xarelto’s Orange Book position historically included a layered estate rather than a single blocking patent. The relevant categories were:

Compound and active-ingredient patents

These patents protect rivaroxaban itself or closely related chemical subject matter. Their commercial value declines sharply after expiration because a generic applicant can generally compete with the active ingredient once regulatory requirements are satisfied.

Method-of-use patents

These patents cover specific therapeutic uses, patient populations, dosing regimens or combinations. Their practical value depends on whether the generic applicant can use a section viii statement to omit the patented indication from its labeling.

Formulation patents

Formulation claims can protect dosage forms, excipients, release characteristics, particle properties or manufacturing parameters. They may create a more durable barrier if the generic product cannot avoid the claims through a design-around.

Pediatric-use patents

Pediatric exclusivity or pediatric-use patent rights may affect approval timing without providing the same broad product protection as a compound patent. Their effect depends on the FDA-listed patent and the product’s approved indications.

Orange Book listing is a regulatory notice mechanism. It does not constitute a final determination that a listed patent is valid or infringed.

How strong was Bayer’s patent estate?

Bayer’s Xarelto estate was commercially meaningful because it combined several patent categories with regulatory exclusivity and a high-value branded product. Its strength was mixed by claim type.

Estate component	Relative strength	Commercial assessment
Original compound protection	Low after expiration	The primary active-ingredient barrier was no longer the principal long-term defense by the 2021 litigation period
Method-of-use patents	Moderate	Value depended on indication-specific labeling and the ability to enforce use claims against generic sales
Formulation patents	Moderate to strong	Potentially important if the claims covered the marketed dosage form and were difficult to design around
Manufacturing know-how	Moderate	Can delay or increase the cost of generic development but does not independently prevent approval absent patent claims
Regulatory exclusivity	Time-limited	Supports delay but expires independently of patent validity
Settlement network	Commercially significant	A coordinated resolution can preserve a controlled launch sequence across several generic manufacturers

The estate was stronger as a portfolio than as any individual patent. Aurobindo’s settlement reduced Bayer’s litigation risk, but it also removed the possibility of a court decision that might have confirmed broad enforceability.

Did the case involve biosimilar risk?

No. Biosimilar law was not the relevant framework.

Rivaroxaban is a chemically synthesized small-molecule drug. Aurobindo pursued an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Biologics Price Competition and Innovation Act. The relevant competitive threat was generic substitution, not biosimilar interchangeability.

What litigation affected Xarelto generic entry?

Bayer and related entities brought multiple Hatch-Waxman actions against generic manufacturers that submitted Paragraph IV certifications concerning Xarelto patents. The defendants included major generic companies such as Aurobindo and other ANDA sponsors.

The litigation strategy had three commercial objectives:

• Preserve patent protection beyond expiration of the earliest Xarelto patents;
• Prevent uncoordinated at-risk launches;
• Negotiate staggered or common launch dates with multiple generic applicants.

The Aurobindo case should therefore be evaluated together with related Xarelto cases. A settlement with one defendant did not automatically resolve the legal position of other ANDA applicants, although coordinated settlements could create a broader market-entry schedule.

What was the FDA regulatory status?

Xarelto was FDA-approved and marketed in the United States. Aurobindo’s product was an ANDA-based generic application, so FDA approval depended on demonstrating pharmaceutical equivalence, bioequivalence and compliance with applicable labeling and manufacturing requirements.

The patent case did not itself grant FDA approval. Aurobindo still needed final FDA approval, and any approval would be subject to:

• Remaining Orange Book patents;
• Labeling carve-outs;
• Regulatory deficiencies or deficiencies in the ANDA;
• Manufacturing-site readiness;
• Settlement restrictions;
• Applicable exclusivity periods.

What revenue exposure did the litigation create?

The economic exposure was tied to Xarelto’s large U.S. anticoagulant market and the concentration of sales in a small number of approved strengths and indications. Generic entry typically produces rapid price erosion after launch, although the magnitude depends on the number of entrants, the presence of an authorized generic and the timing of formulary substitution.

For Bayer and its commercial partners, the main revenue risks were:

• Earlier-than-settlement generic launch;
• Multiple generic entrants launching simultaneously;
• Loss of preferred formulary status;
• Price competition across all major tablet strengths;
• Erosion of high-volume atrial-fibrillation and venous-thromboembolism prescriptions;
• Substitution by competing anticoagulants, including apixaban.

A controlled settlement launch can preserve branded sales before entry but rarely prevents substantial erosion once several generic suppliers are active.

How does Xarelto compare with Eliquis?

Xarelto and Eliquis are competing oral factor Xa inhibitors. Eliquis, whose active ingredient is apixaban, has its own patent and settlement structure. The two products compete in atrial fibrillation, venous thromboembolism and related cardiovascular uses.

Issue	Xarelto	Eliquis
Active ingredient	Rivaroxaban	Apixaban
Drug class	Direct factor Xa inhibitor	Direct factor Xa inhibitor
Generic litigation	Multiple Hatch-Waxman cases	Separate, extensive patent litigation
Key patent risks	Methods, formulations and later Orange Book patents	Compound, formulation and method-of-use patents
Competitive impact of generic entry	Likely pressure on Bayer/Janssen sales	Likely pressure on Bristol Myers Squibb/Pfizer sales
Substitution dynamics	Competes with Eliquis and warfarin	Competes with Xarelto and warfarin

Aurobindo’s settlement affected the timing of generic rivaroxaban competition. It did not resolve Eliquis patent rights or determine the timing of apixaban generic entry.

What is the litigation status of 1:21-cv-01575?

The case was resolved and dismissed after settlement. There was no reported final merits opinion holding the asserted patents valid and infringed, invalid, or not infringed.

The principal legal effect of the docket outcome is contractual. The settlement determined Aurobindo’s rights and restrictions concerning generic rivaroxaban entry. The docket disposition should not be treated as a patent-validity ruling.

Key Takeaways

• Bayer sued Aurobindo in Delaware over an ANDA for generic rivaroxaban, the active ingredient in Xarelto.
• The case was a Hatch-Waxman Paragraph IV action under 35 U.S.C. § 271(e)(2).
• Bayer relied on a layered patent estate covering methods of use and pharmaceutical formulations, not only the original rivaroxaban compound.
• The litigation ended in settlement and dismissal without a reported merits judgment.
• Aurobindo’s launch rights were controlled by the confidential settlement and applicable FDA approval requirements.
• The case involved a small-molecule generic, not a biosimilar.
• Xarelto’s commercial exposure depended on coordinated generic entry, the number of approved competitors and the timing of formulary substitution.
• The dismissal does not establish that Bayer’s asserted patents were valid, enforceable or infringed.

FAQs

Did Aurobindo win Bayer’s Xarelto patent case?

No merits victory was reported. The case ended through settlement and dismissal, so the court did not issue a final ruling on validity or infringement.

Was Aurobindo authorized to sell generic rivaroxaban immediately after dismissal?

No. Dismissal did not automatically authorize immediate commercial launch. Aurobindo remained subject to the settlement terms, FDA approval requirements and any surviving patent or exclusivity restrictions.

Did the lawsuit challenge all Xarelto patents?

No. A Hatch-Waxman complaint addresses the patents and claims identified in that action. Other Orange Book-listed patents or later-issued patents could affect separate ANDAs and later launch analysis.

Could Aurobindo launch with a skinny label?

Potentially, if the ANDA excluded patented indications through a section viii statement and the FDA accepted the labeling. The feasibility depended on the specific patent claims, approved indications and proposed product label.

Does the settlement establish the value of Bayer’s Xarelto patents?

No. A settlement reflects the parties’ assessment of litigation risk, launch economics and commercial objectives. It is not a judicial finding of patent validity or infringement.

References

1. U.S. District Court for the District of Delaware. (2021). Bayer Healthcare LLC v. Aurobindo Pharma Ltd., No. 1:21-cv-01575. PACER/CourtListener docket records.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Xarelto prescribing information. Janssen Pharmaceuticals, Inc. and Bayer HealthCare Pharmaceuticals Inc.

4. U.S. Code. (2024). 21 U.S.C. § 355(j), abbreviated new drug applications.

5. U.S. Code. (2024). 35 U.S.C. § 271(e)(2), infringement relating to drug applications.